Soriot, Schleifer, Perreault named top global CEOs — but gone are pharma's golden years

CEOs of giant companies can be remembered for a plethora of things: the deals they strike, the people they hire and fire, the words they utter in interviews, and so on. But for the Street, it’s the financial performance that defines any tenure. The Harvard Business Review has just dropped the 2019 edition of its calculations on that while blending in a dash of the environmental, social and governance factors that have increasingly concerned investors.